What Cancer52 does

Cancer52 is a UK-registered charity alliance (registered charity number 1174569; company limited by guarantee number 7994413) comprising over 100 cancer charities that focus on rare and less common cancers — defined as those outside the four most common types (breast, bowel, lung, prostate). The organization, headquartered in London and operating with approximately 11 employees under CEO Jane Lyons, was founded in 2006 and exists to address a documented inequality: rare and less common cancers account for 47% of UK cancer diagnoses and 55% of UK cancer deaths, yet have historically been under-represented in policy, services, and research funding.

The alliance operates as a convening and advocacy platform rather than a technology product company. Its core activities include unifying, informing, and empowering member organizations; capturing the patient voice through surveys and case studies; and transmitting that voice to policymakers, the NHS, NICE, NCRI, and research institutions. Service and publication assets include the annual Big Cancer52 Conversation (a flagship event series launched in 2023 and expanded to multiple UK cities), the Research Spend Report (co-developed with NCRI), the State of the Nation Report, the Improving Diagnosis Report (co-developed with GRAIL and Incisive Health), the ACT NOW for Cancer initiative, a rare cancers directory, a health information resource library, and recurring member bulletins.

Cancer52's revenue model is donation-based, supported through the JustGiving platform, with additional income from event sponsorship (including from GSK and The National Lottery Community Fund) and likely member contributions. It does not charge for membership or services and has no publicly disclosed revenue figure. The organization holds no patents, has not raised traditional funding rounds, and operates exclusively in the United Kingdom. Its competitive position rests on being the only coalition of its scale in this disease sub-segment, supported by formal partnerships with NHS England, NICE, NCRI, Genomics England, GRAIL, and Incisive Health.

Name

Cancer52

Legal name

Cancer52

Website

https://cancer52.org.uk

Company type

Private

Founded year

2006

Operating status

Operating

Headcount range

11–50 employees

Short description

Cancer52 is a UK-registered charity alliance of over 100 cancer charities that advocates for patients with rare and less common cancers, which account for 47% of UK diagnoses and 55% of UK cancer deaths. Based in London with 11 employees under CEO Jane Lyons, it convenes members, publishes policy reports, and engages NHS England, NICE, and research bodies to influence cancer policy and funding.

Ownership category

akta.pro rank

Headquarters

HQ city

London

HQ country

United Kingdom

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Others

Revenue model

1. Donations and Fundraising: Cancer52 operates as a registered charity (1174569) and accepts donations through platforms like JustGiving to support its work as an alliance of cancer charities advocating for rare and less common cancer patients.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Cancer52 is a charity alliance of over 100 cancer charities that unifies, informs and empowers member organizations while capturing the patient voice for rare and less common cancers and channeling it into national cancer policy, research, and service delivery. It delivers this through member communications, published reports (Research Spend Report, State of the Nation Report, Improving Diagnosis Report), policy consultations, and the annual Big Cancer52 Conversation event.

Product overview

Cancer52 is a charity alliance organization, not a technology product company. It operates as a coalition of over 100 cancer charities united to address inequality in rare and less common cancers. The organization provides advocacy services, publishes research reports (Research Spend Report, State of the Nation Report, Improving Diagnosis Report), hosts the annual Big Cancer52 Conversation event, maintains a directory of rare cancer charities, offers a health information resource library, and runs member bulletins and the ACT NOW for Cancer initiative. These services support the organization's mission to unify, inform, and empower member organizations while influencing cancer policy at national level.

Differentiator

Problem solved

Functional benefit

Products and services

• Cancer52 Charity Alliance Core membership coalition of over 100 UK cancer charities focused on rare and less common cancers, offering unified advocacy, policy engagement, and patient voice amplification for member organizations and the patients they serve.
• Research Spend Report Published report analysing research funding by Cancer52 members and NCRI partners, documenting disparities between rare/less common cancers and common cancers, intended for policymakers, researchers and member charities.
• The Big Cancer52 Conversation Annual in-person event series bringing together member charities, policymakers, NHS bodies, clinicians and researchers to discuss rare and less common cancer policy, early diagnosis and care in the UK.
• Improving Diagnosis Report Published report examining patient and clinician perspectives on increasing early diagnosis in rare and less common cancers, with policy recommendations for the National Cancer Plan for England.
• State of the Nation Report: No Cancer Too Rare Policy review report examining developments since the 2024 UK General Election that will shape cancer services for rare and less common cancers.
• ACT NOW for Cancer Initiative showcasing real-world case studies from Cancer52 member charities, demonstrating impact for people affected by rare and less common cancers.
• Rare and Less Common Cancers Directory Searchable directory of Cancer52 member charities organized by cancer type, helping patients, carers and the public find information and support for specific rare and less common cancers.
• Cancer52 Bulletins Regular email bulletins providing member charities and stakeholders with updates on news, events, policy developments and organizational activities.

Named customers1 record

Segments1 record

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Six partnerships are on record, tiered core.

• GRAILcoreStrategic or Co-development PartnerCancer52 worked with GRAIL (biotech company) on the 'Improving Diagnosis' report, collaborating on patient and clinician insights around early diagnosis for rare and less common cancers.
• Incisive HealthcoreStrategic or Co-development PartnerCancer52 collaborated with Incisive Health consultancy on the 'Improving Diagnosis' report, taking a deep dive led by patients, carers, and clinicians.
• NHS EnglandcoreStrategic or Co-development PartnerCancer52 engages with NHS England on cancer policy, early diagnosis initiatives, and the National Cancer Plan. The organization participates in consultations and provides patient voice input.
• NCRI (National Cancer Research Institute)coreStrategic or Co-development PartnerCancer52 collaborates with NCRI on the Research Spend Report, combining Cancer52 member data with NCRI partner data for comprehensive analysis of research spending on rare and less common cancers.
• Genomics EnglandcoreStrategic or Co-development PartnerGenomics England hosts Cancer52 Roundtable discussions, providing a platform for engagement on genomics and rare cancer research.
• NICEcoreStrategic or Co-development PartnerCancer52 engages with NICE on public involvement programmes and consultations, contributing patient perspectives to NICE methods and processes reviews.

Scale indicators2 records

Recent moves6 records

Expansion highlights4 records

Broad incumbents

• Cancer Research UK: The UK's largest cancer charity, funding research, influencing policy and providing patient information. Overlaps significantly with Cancer52's policy and research-funding advocacy remit but as a single, much larger organisation rather than an alliance.
• Macmillan Cancer Support: Major UK cancer charity providing services and influencing policy on cancer patient experience. Comparable in policy influence scope to Cancer52 but operates as a single direct-service charity rather than a charity alliance.

Direct peers

• Genetic Alliance UK: UK charity alliance representing hundreds of patient organisations supporting people affected by genetic, rare and undiagnosed conditions. Operates a near-identical coalition model advocating for under-represented patient communities in NHS and policy fora.
• Rare Disease UK: UK national campaign run by Genetic Alliance UK focused specifically on rare diseases. Highly comparable alliance-style advocacy structure targeting the same NHS policy-making environment that Cancer52 engages with.
• EURORDIS - Rare Diseases Europe: European alliance of over 1,000 rare-disease patient organisations. Operates an analogous multi-charity advocacy and policy-influence model with which Cancer52 shares NHS-aligned patient representation objectives.
• European Cancer Patient Coalition: European umbrella coalition of over 400 cancer patient organisations. The most direct continental analogue to Cancer52's cancer-charity alliance model, operating across jurisdictions but with the same advocacy and patient-voice mandate.

Emerging players

• Anthony Nolan: UK charity focused on blood cancers and stem-cell transplantation. A Cancer52 member-style organisation operating in a specific rare cancer niche, illustrating the scale and specialisation of Cancer52's constituent members.
• Blood Cancer UK: UK charity dedicated to blood cancer research and patient support. Representative of the type of single-disease member charity within Cancer52's alliance, illustrating the typical size and remit of Cancer52's 100+ member organisations.

Regional players

• National Organization for Rare Disorders (NORD): US-based federation of patient organisations and advocacy groups for rare diseases. Functions as the American equivalent of Cancer52's coalition model but in a different regulatory and payer environment.

Others

• National Cancer Research Institute (NCRI): UK partnership of cancer research funders that Cancer52 actively collaborates with on the Research Spend Report. An adjacent ecosystem participant rather than a competitor, but sharing the policy and research coordination function Cancer52 performs for charities.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xtwitter.com/Cancer52org
• Facebookfacebook.com/Cancer52org
• LinkedInlinkedin.com/company/cancer52

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cancer52